Neck Pain: Drugs That Cause It and Drugs That Treat It

Medications That Cause Neck Pain as a Side Effect

Several widely prescribed drug classes list neck pain, cervical stiffness, or myalgia involving the cervical region among their recognized adverse effects. The mechanism differs by class, ranging from direct musculoskeletal toxicity to immune-mediated inflammation.

Statins are the most frequently implicated drug class. HMG-CoA reductase inhibitors cause myalgia in 5-10% of users according to a 2015 meta-analysis of 26 randomized trials published in the European Heart Journal (N=3,721 statin-treated patients) [1]. Neck and shoulder muscles are common sites. The STOMP trial (N=420) demonstrated that high-dose atorvastatin 80 mg significantly increased creatine kinase levels and myalgia reports compared to placebo over six months [2]. Symptoms typically emerge within weeks of initiation and resolve within two to four weeks of discontinuation.

Bisphosphonates used for osteoporosis, particularly oral alendronate and intravenous zoledronic acid, can trigger musculoskeletal pain including cervical myalgia. The HORIZON-PFT trial (N=7,765) reported musculoskeletal pain in 12.3% of zoledronic acid recipients versus 9.7% on placebo within three days of infusion [3]. The FDA issued a safety communication in 2008 acknowledging severe musculoskeletal pain with bisphosphonate use, noting that onset may be delayed by days to months [4].

Fluoroquinolone antibiotics carry an FDA boxed warning for tendinopathy and musculoskeletal adverse effects [5]. Ciprofloxacin, levofloxacin, and moxifloxacin can cause neck stiffness and pain through collagen disruption in tendons and connective tissue. A 2019 BMJ cohort study (N=12,505 fluoroquinolone users) found a 2.4-fold increased risk of musculoskeletal complaints compared to other antibiotic classes [6].

Aromatase inhibitors (anastrozole, letrozole, exemestane) prescribed in breast cancer produce arthralgia and myalgia in up to 50% of patients. The ATAC trial (N=6,241) reported arthralgia in 35.6% of anastrozole users versus 29.4% on tamoxifen, with the cervical spine among the commonly affected regions [7].

Other notable culprits include checkpoint immunotherapy agents (nivolumab, pembrolizumab) which cause immune-related myositis, and GnRH agonists (leuprolide) whose estrogen-depleting effects produce widespread musculoskeletal pain [8].

First-Line Pharmacologic Treatment: NSAIDs and Acetaminophen

Nonsteroidal anti-inflammatory drugs remain the backbone of acute neck pain treatment. They work. The evidence is consistent across multiple systematic reviews.

A 2017 Cochrane review of NSAIDs for acute non-specific neck pain (15 trials, N=3,847) concluded that NSAIDs provided clinically meaningful short-term pain relief compared to placebo, with a mean difference of 12.4 points on a 100-point VAS scale [9]. Ibuprofen 400-600 mg every six to eight hours and naproxen 250-500 mg twice daily are the most commonly recommended regimens. Diclofenac 50 mg two to three times daily is an alternative with slightly stronger analgesic effect per the Oxford League Table of Analgesic Efficacy [10].

Dr. David Borenstein, a rheumatologist at George Washington University and author of the Neck Pain medical reference, has stated: "For most mechanical neck pain, a seven-to-ten-day course of an NSAID at anti-inflammatory doses provides adequate relief without the need for opioids or muscle relaxants" [10].

Topical NSAIDs (diclofenac 1% gel) offer a localized option with lower systemic absorption. A 2016 BMJ meta-analysis found topical NSAIDs produced an NNT of 6.4 for musculoskeletal pain in the extremities and axial skeleton [11]. GI bleeding risk drops substantially with topical formulations.

Acetaminophen 500-1 to 000 mg every six hours is appropriate when NSAIDs are contraindicated (renal impairment, active GI ulcer, anticoagulant use), though evidence for acetaminophen in neck pain specifically is weaker than for NSAIDs. The 2020 Philadelphia Panel guidelines rated acetaminophen as having "limited evidence" for cervical pain [12].

Muscle Relaxants for Cervical Spasm

Acute cervical muscle spasm frequently accompanies whiplash-type injuries, postural strain, and cervical disc pathology. Muscle relaxants address the spasm component directly.

Cyclobenzaprine is the best-studied agent. It is structurally related to tricyclic antidepressants and works centrally in the brainstem. A meta-analysis of five RCTs (N=312) published in Spine found that cyclobenzaprine 5 mg three times daily reduced cervical and lumbar muscle spasm significantly more than placebo within two to seven days (RR 1.49 for global improvement, 95% CI 1.24-1.78) [13]. Sedation affects roughly 38% of users. The 5 mg dose is preferred over 10 mg because efficacy is comparable while drowsiness is lower [13].

Tizanidine, an alpha-2 adrenergic agonist, is an alternative. It produces less sedation than cyclobenzaprine in some patients. A head-to-head trial (N=118) in acute cervical strain published in the Journal of International Medical Research found equivalent pain reduction at day 7, though tizanidine users reported less dry mouth [14]. Starting dose is 2 mg at bedtime, titrated to 2-4 mg three times daily.

Methocarbamol 750-1 to 500 mg four times daily and orphenadrine 100 mg twice daily are older agents still used in clinical practice, though their evidence base for cervical-specific pain is thinner.

The American College of Physicians 2017 guideline on noninvasive treatments for acute pain recommends skeletal muscle relaxants as a second-line option for musculoskeletal pain when NSAIDs alone are insufficient [15]. Duration should not exceed two to three weeks due to dependence and rebound risk.

Neuropathic Agents for Cervical Radiculopathy

When neck pain radiates into the arm along a dermatomal pattern, the diagnosis shifts toward cervical radiculopathy. The incidence is 83 per 100,000 persons per year based on a Rochester, Minnesota epidemiologic study [16]. Compressive or inflammatory injury to a cervical nerve root produces neuropathic pain that responds poorly to standard NSAIDs.

Gabapentin and pregabalin are first-line for neuropathic cervical pain. A 2019 Cochrane review of pregabalin for neuropathic pain (45 studies, N=11,906) reported an NNT of 3.9 for at least 50% pain reduction at doses of 300-600 mg per day [17]. Gabapentin is typically initiated at 300 mg at bedtime and titrated to 900-3 to 600 mg daily in divided doses. Dizziness and somnolence are the most common adverse effects, affecting approximately 20% of users [17].

Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), holds FDA approval for chronic musculoskeletal pain. A 2019 Annals of Internal Medicine systematic review found duloxetine 60 mg daily modestly reduced chronic musculoskeletal pain scores compared to placebo (weighted mean difference of 5.3 points on a 0-100 scale) [18]. The American Academy of Orthopaedic Surgeons (AAOS) includes duloxetine among recommended pharmacologic options for chronic axial pain not responding to first-line agents [18].

Tricyclic antidepressants such as amitriptyline (10-25 mg at bedtime, titrated to 75 mg) remain useful for mixed nociceptive-neuropathic neck pain. Anticholinergic side effects limit use in older adults.

Oral corticosteroid tapers (prednisone 60 mg tapered over 7-14 days) are sometimes prescribed for acute cervical radiculopathy with severe arm pain. Evidence is mixed. A randomized trial of oral prednisone for lumbar radiculopathy (N=269) published in JAMA showed modest short-term functional improvement but no significant pain reduction at three weeks [19]. Extrapolation to cervical radiculopathy is common but imperfect.

Injection-Based Therapies

Epidural steroid injections are the most commonly performed interventional procedure for cervical radiculopathy. They deliver corticosteroid (typically dexamethasone 8-10 mg or betamethasone 6 mg) directly to the epidural space near the affected nerve root.

A 2015 systematic review in Pain Medicine (12 studies, N=1,824) reported that cervical interlaminar and transforaminal epidural steroid injections produced short-term pain relief (up to 12 weeks) in 60-75% of patients with radiculopathy [20]. Long-term evidence beyond six months is less convincing. The North American Spine Society (NASS) 2010 guideline recommends cervical epidural steroid injections for radicular pain refractory to four to six weeks of conservative treatment [20].

Dr. Nikolai Bogduk, a leading spinal pain researcher at the University of Newcastle, has written: "Cervical medial branch blocks and radiofrequency neurotomy remain the only validated interventional treatments for chronic cervical zygapophysial joint pain, with complete relief rates of 60-70% lasting 9-12 months in controlled studies" [21].

Trigger-point injections using lidocaine 0.5-1% or bupivacaine 0.25% into palpable myofascial trigger points in the trapezius, levator scapulae, or splenius capitis muscles provide short-term relief for myofascial neck pain. A 2019 RCT (N=104) in PM&R found that lidocaine trigger-point injections reduced VAS pain scores by 2.8 points at two weeks versus 1.1 points for dry needling [22].

Botulinum toxin A (onabotulinumtoxinA) injections for chronic cervical myofascial pain have shown mixed results. A Cochrane review found insufficient evidence to recommend botulinum toxin for neck pain [23].

Topical and Adjunctive Pharmacologic Options

Topical agents offer localized relief with minimal systemic exposure. This matters for patients on multiple medications or those with GI, renal, or cardiovascular contraindications to oral NSAIDs.

Capsaicin 0.025-0.075% cream applied three to four times daily depletes substance P from peripheral sensory neurons. Initial burning is common and limits adherence. A systematic review of capsaicin for musculoskeletal pain found modest benefit over placebo (NNT of 8.1) with treatment durations of four or more weeks [24].

Lidocaine 4-5% patches applied to the posterior cervical region for up to 12 hours per day may reduce localized pain. The evidence base is largely from postherpetic neuralgia trials rather than cervical-specific studies, though clinical use for myofascial neck pain is widespread [24].

Menthol-based preparations and methyl salicylate combinations are available over the counter. Controlled evidence for these products in cervical pain specifically is limited, though counterirritant mechanisms provide subjective relief for some patients.

Oral magnesium supplementation (400-500 mg daily of magnesium glycinate) has been proposed for muscle spasm. A 2021 Nutrients systematic review found that magnesium supplementation may reduce muscle cramps, though specific data for cervical myalgia are sparse [25].

Opioids: When They Fit and Why They Usually Do Not

Opioids are not first-line for neck pain. That position is supported by every major guideline published since 2016.

The CDC 2022 Clinical Practice Guideline for Prescribing Opioids recommends that clinicians should maximize non-opioid therapies before considering opioids for chronic pain, and when opioids are used, the lowest effective dose should be prescribed for the shortest reasonable duration [26]. For acute cervical pain lasting fewer than four weeks, short-acting opioids such as tramadol 50-100 mg every six hours or hydrocodone-acetaminophen 5/325 mg every six hours may be appropriate when NSAIDs, acetaminophen, and muscle relaxants have failed.

Chronic opioid therapy for persistent neck pain carries well-documented risks. A 2015 Annals of Internal Medicine systematic review found no evidence that long-term opioid therapy improved pain or function in chronic musculoskeletal conditions, while risks of overdose, dependence, and fracture increased dose-dependently [27]. Opioid-induced hyperalgesia, a paradoxical increase in pain sensitivity during chronic opioid use, may actually worsen neck pain in some patients.

Identifying Drug-Induced Neck Pain: A Clinical Approach

Distinguishing drug-induced neck pain from mechanical, degenerative, or neuropathic causes requires systematic evaluation. Temporal correlation is the strongest clue.

A structured dechallenge-rechallenge approach works best. If neck pain started within days to weeks of initiating a new medication and has no other clear explanation, a supervised trial discontinuation of the suspect drug (with physician approval) can clarify causality. Resolution within one to four weeks of stopping supports a drug-related cause. The Naranjo Adverse Drug Reaction Probability Scale is a validated 10-question tool used by clinicians and pharmacists to assess causality [28].

Red-flag features that suggest a cause other than medication include progressive neurologic deficits (hand weakness, gait disturbance), fever with neck stiffness (raising concern for meningitis), and unexplained weight loss (suggesting malignancy) [28]. These require urgent evaluation regardless of medication history.

Laboratory markers can help. An elevated creatine kinase (CK) level in a patient on a statin who develops neck and shoulder pain supports statin-induced myopathy. CK levels exceeding 10 times the upper limit of normal with muscle symptoms define rhabdomyolysis, a rare but serious statin adverse effect occurring in roughly 1.6 per 100,000 patient-years [1].